StockData
Atara Biotherapeutics, Inc. logo

Atara Biotherapeutics, Inc. (ATRA) stock

ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/30
$6.50+0.10 (+1.56%)

Close on Nov 17, 2026Market cap $65.25MP/E –Yield –

Atara Biotherapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Atara Biotherapeutics's operating income for the twelve months ending Jun 30, 2026 was -$14.23M, down 277.0% year over year. For fiscal 2025 it was $35.86M. The highest annual figure on record is $35.86M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$35.86M–
FY2024Dec 31, 2024-$83.44M–
FY2023Dec 31, 2023-$276.01M–
FY2022Dec 31, 2022-$280.51M–
FY2021Dec 31, 2021-$340.46M–
FY2020Dec 31, 2020-$309.05M–
FY2019Dec 31, 2019-$295.68M–
FY2018Dec 31, 2018-$237.11M–
FY2017Dec 31, 2017-$121.53M–
FY2016Dec 31, 2016-$81.24M–
FY2015Dec 31, 2015-$58.45M–
FY2014Dec 31, 2014-$28.16M–
FY2013Dec 31, 2013-$8.62M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.72M-247.6%
Q1 FY2026Mar 31, 2026-$3.37M-108.7%
Q4 FY2025Dec 31, 2025-$2.56M–
Q3 FY2025Sep 30, 2025-$3.57M–
Q2 FY2025Jun 30, 2025$3.20M–
Q1 FY2025Mar 31, 2025$38.80M–
Q4 FY2024Dec 31, 2024-$12.20M–
Q3 FY2024Sep 30, 2024-$21.76M–
Q2 FY2024Jun 30, 2024-$18.23M–
Q1 FY2024Mar 31, 2024-$31.25M–
Q4 FY2023Dec 31, 2023-$59.96M–
Q3 FY2023Sep 30, 2023-$69.61M–
Q2 FY2023Jun 30, 2023-$71.41M–
Q1 FY2023Mar 31, 2023-$75.02M–
Q4 FY2022Dec 31, 2022-$75.54M–
Q3 FY2022Sep 30, 2022-$84.62M–
Q2 FY2022Jun 30, 2022-$32.13M–
Q1 FY2022Mar 31, 2022-$88.22M–
Q4 FY2021Dec 31, 2021-$93.40M–
Q3 FY2021Sep 30, 2021-$84.81M–
Q2 FY2021Jun 30, 2021-$84.00M–
Q1 FY2021Mar 31, 2021-$78.25M–
Q4 FY2020Dec 31, 2020-$81.70M–
Q3 FY2020Sep 30, 2020-$74.71M–
Q2 FY2020Jun 30, 2020-$77.95M–
Q1 FY2020Mar 31, 2020-$74.70M–
Q4 FY2019Dec 31, 2019-$79.70M–
Q3 FY2019Sep 30, 2019-$72.56M–
Q2 FY2019Jun 30, 2019-$75.54M–
Q1 FY2019Mar 31, 2019-$67.89M–
Q4 FY2018Dec 31, 2018-$81.82M–
Q3 FY2018Sep 30, 2018-$60.22M–
Q2 FY2018Jun 30, 2018-$52.62M–
Q1 FY2018Mar 31, 2018-$42.45M–
Q4 FY2017Dec 31, 2017-$35.80M–
Q3 FY2017Sep 30, 2017-$31.66M–
Q2 FY2017Jun 30, 2017-$27.91M–
Q1 FY2017Mar 31, 2017-$26.16M–
Q4 FY2016Dec 31, 2016-$18.75M–
Q3 FY2016Sep 30, 2016-$25.94M–

More Atara Biotherapeutics figures

See a number that looks wrong?